Skip to main content
. 2020 Jan 6;15:3. doi: 10.1186/s13023-019-1280-5

Table 2.

Accessibility and prescription of EMA-approved OMPs for HMDs in the 18 individual MetabERN participating countries

graphic file with name 13023_2019_1280_Tab2_HTML.jpg

* All EU patients were registered in the NL in 2018

** Marketing authorization under discussion